Citation Payola?

A transgenic mouse company is paying researchers who mention its animal models in scientific papers.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, MIKE SCHMIDCompanies of all stripes frequently flood customer inboxes with special email offers. But a deal offered by Cyagen Biosciences, which provides transgenic mice among other products and services to life-science researchers, has raised hackles across the Internet. The California-based company sent out an email offer that encouraged researchers to mention Cyagen in the methods sections of published papers, promising store credit to willing scientists; authors could get $100 × the journal’s impact factor (IF) for citing the company in their papers.

Cyagen apparently began sending out the email offer in June, but last week, researchers lit up Twitter with outraged reactions to the deal. “Cyagen Biosciences offers $100 in rewards or more if high IF for citing them in your publication! Outrageous!” tweeted Oregon State University geneticist Niklaus Grunwald. The marketing ploy garnered significant attention on Friday (August 14), when Ben Goldacre excoriated Cyagen on his blog. “I would imagine that this is something journal editors will be interested in, and concerned by,” he wrote. “We worry about ‘conflict of interest’ a lot in science, and especially medicine: if someone has shares in a company, or receives money from it, and their publication discusses that company’s products, then this needs to be declared in the paper. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies